SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive hematologic malignancy with poor prognosis.
• Known genetic alterations in T-PLL include chromosomal translocations and mutations in genes like ATM and JAK/STAT pathway members.
• Understanding the molecular drivers of T-PLL is crucial for developing targeted therapies.

Purpose of the Study:

• To identify novel recurrently mutated genes in T-cell prolymphocytic leukemia (T-PLL).
• To expand the understanding of molecular pathways involved in T-PLL pathogenesis.
• To investigate the role of the SAMHD1 gene in T-PLL.

Main Methods:

• Targeted mutation analysis of 40 selected genes in 28 T-PLL samples.
• Whole-exome sequencing of an additional five T-PLL cases.
• Identification and analysis of nonsynonymous mutations and deletions.

Main Results:

• Nonsynonymous mutations were found in 30 of 40 genes analyzed, with 18 genes recurrently mutated.
• Previously unreported recurrently mutated genes in T-PLL include SAMHD1, HERC1, HERC2, PRDM2, PARP10, PTPRC, and FOXP1.
• Destructive mutations or deletions in the SAMHD1 gene were observed in approximately 20% of T-PLL cases, suggesting its role as a tumor suppressor.

Conclusions:

• The study significantly expands the landscape of molecular alterations in T-PLL.
• Recurrent mutations in genes involved in JAK/STAT signaling (PTPRC), epigenetic regulation (PRDM2), and DNA damage repair (SAMHD1, PARP10, HERC1, HERC2) were identified.
• The tumor suppressor gene SAMHD1 is implicated as a major player in T-PLL pathogenesis, with significant alterations in about 20% of patients.